<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mastitis and breast abscess in infants younger than two months</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mastitis and breast abscess in infants younger than two months</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Mastitis and breast abscess in infants younger than two months</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nirupama K De Silva, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Régine Fortunov, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jan E Drutz, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 03, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The clinical features, evaluation, and management of mastitis and breast abscess in infants &lt;2 months will be discussed in this topic review. Mastitis and breast abscess are less common in infants ≥2 months than in younger infants. The evaluation and management of mastitis in infants ≥2 months are similar to those in older children. Mastitis and breast abscess in older children and adolescents, lactational mastitis, and breast infections in adult women are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/110660.html" rel="external">"Mastitis and breast abscess in children and adolescents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/798.html" rel="external">"Lactational mastitis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/794.html" rel="external">"Nonlactational mastitis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/795.html" rel="external">"Primary breast abscess"</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span>Most cases of mastitis and breast abscess in infants are caused by <em>Staphylococcus aureus</em> [<a href="#rid1">1-8</a>]. Less common causes include gram-negative enteric organisms (eg, <em>Escherichia coli</em>, <em>Salmonella</em>), anaerobes, and group B <em>Streptococcus</em> (<em>Streptococcus agalactiae</em>) [<a href="#rid1">1,4,6,7,9-13</a>].</p><p class="headingAnchor" id="H6"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of infant mastitis typically involves spread of pathogenic bacteria from the skin and/or mucous membranes to the breast parenchyma through the nipple [<a href="#rid3">3,5,14</a>]. In infants with systemic infection (which is usually gram-negative), bacteria also may spread to the breast hematogenously.</p><p>Predisposing factors include stimulation of the breast by placental and maternal hormones (estrogens), which result in physiologic breast hypertrophy in full term infants, and maternal skin or soft-tissue infection in the postpartum period [<a href="#rid3">3,13,15,16</a>]. It is thought that premature babies have underdeveloped mammary glands, which are less likely to develop infection [<a href="#rid4">4</a>]. Breast massage may also increase risk [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H7"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>During the first year of life, mastitis typically occurs in full-term infants who are younger than two months. Peak incidence of mastitis appears to occur earlier (at two weeks of life) than mastitis with abscess (four weeks of life) [<a href="#rid2">2,18</a>].</p><p>During the first two weeks of life, mastitis occurs with equal frequency in males and females [<a href="#rid2">2,3</a>]. Thereafter, it is more common in females, with a female:male ratio of approximately 2:1 [<a href="#rid3">3</a>]. A possible explanation for the predominance in females is the tendency for breast hypertrophy to persist longer than in males [<a href="#rid2">2,4</a>].</p><p>Mastitis in infants usually is unilateral and remains localized [<a href="#rid1">1-4,7</a>]. Characteristic clinical features include marked erythema, tenderness, and induration of the affected breast  (<a class="graphic graphic_picture graphicRef110965" href="/z/d/graphic/110965.html" rel="external">picture 1</a>) [<a href="#rid1">1</a>]. There may be associated skin lesions (eg, pustules, bullae) [<a href="#rid17">17,18</a>]. The axillary lymph nodes may be enlarged and tender [<a href="#rid5">5,19</a>]. More than one-half of infants with mastitis develop abscesses, which can be indicated by fluctuance [<a href="#rid5">5,7,18,20</a>]. Purulent nipple discharge occurs in approximately 20 percent of cases [<a href="#rid7">7</a>].</p><p>Systemic symptoms also may occur and may indicate more severe infection. In a retrospective multicenter cohort of 657 infants ≤90 days of age with mastitis, systemic symptoms included fever in 21 percent and poor feeding or fussiness in 10 percent [<a href="#rid8">8</a>]. Among the 10 infants with a clinical diagnosis of sepsis or shock, 8 were febrile, 2 were ill appearing, and 2 were neither febrile nor ill appearing.</p><p>Gastrointestinal symptoms may indicate <em>Salmonella</em> or other gram-negative enteric pathogens [<a href="#rid3">3,5</a>].</p><p class="headingAnchor" id="H202681150"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Although infant mastitis usually is uncomplicated, cases of infant mastitis complicated by extensive cellulitis, necrotizing fasciitis, and osteomyelitis have been reported [<a href="#rid3">3,4,21-25</a>].</p><p>Spread of infection beyond the breast is uncommon in well-appearing infants [<a href="#rid3">3,7</a>]. In a series of 94 infants (0 to 120 days) with mastitis, two infants had a positive urine culture; both had systemic findings: A febrile infant with a breast culture positive for <em>S. aureus</em> also had group B <em>Streptococcus</em> isolated from the urine, and an irritable infant with a breast culture positive for coagulase negative <em>Staphylococcus</em> (a possible contaminant) also had <em>E. coli</em> isolated from the urine [<a href="#rid7">7</a>]. Two infants had positive cerebrospinal fluid (CSF) findings: One ill-appearing infant with methicillin-resistant <em>S. aureus</em> breast abscess also had submental abscesses and CSF pleocytosis and was treated for meningitis; the other had CSF culture positive for <em>Klebsiella oxytoca</em> without pleocytosis; repeat culture was negative.</p><p class="headingAnchor" id="H1612703555"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>A clinical diagnosis of mastitis can be made in infants with swelling, erythema, warmth, tenderness, induration, and/or fluctuance of the breast  (<a class="graphic graphic_picture graphicRef110965" href="/z/d/graphic/110965.html" rel="external">picture 1</a>). Fluctuance indicates breast abscess. Ultrasonography is not necessary but can confirm the diagnosis of mastitis or breast abscess if the diagnosis is uncertain [<a href="#rid26">26,27</a>].</p><p>Laboratory evaluation is not necessary to make the diagnosis but helps to guide additional evaluation and management. (See <a class="local">'Additional evaluation'</a> below and <a class="local">'Management'</a> below.)</p><p class="headingAnchor" id="H1936778679"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>In infants younger than two months, the main consideration in the differential diagnosis of mastitis is physiologic breast hypertrophy, which resolves spontaneously [<a href="#rid28">28</a>]. In contrast to mastitis, physiologic breast hypertrophy usually is bilateral and symmetric  (<a class="graphic graphic_picture graphicRef110966" href="/z/d/graphic/110966.html" rel="external">picture 2</a>); the breasts are neither erythematous nor tender; if present, the nipple discharge is milky rather than purulent and does not contain polymorphonuclear white blood cells or bacteria on Gram stain. (See  <a class="medical medical_review" href="/z/d/html/104.html" rel="external">"Breast masses in children and adolescents", section on 'Neonates and infants'</a>.)</p><p>Other considerations in the differential diagnosis of mastitis and breast abscess in infants include hemangioma and lymphangioma (cystic hygroma). (See  <a class="medical medical_review" href="/z/d/html/5794.html" rel="external">"Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications", section on 'Clinical presentation'</a> and  <a class="medical medical_review" href="/z/d/html/5789.html" rel="external">"Vascular lesions in the newborn", section on 'Lymphatic malformations'</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">ADDITIONAL EVALUATION</span><span class="headingEndMark"> — </span>Our suggested evaluation for infants with mastitis includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete blood count with differential</strong> – The white blood cell (WBC) count can help determine the need for lumbar puncture and urine culture; if elevated at baseline, the WBC count may be used to monitor response to therapy, particularly if the infant does not improve as expected.</p><p></p><p class="bulletIndent1">In a retrospective multicenter cohort of 657 infants with mastitis, the median peripheral WBC count was 15,600/microL (interquartile range 12,900 to 19,500/microL) [<a href="#rid8">8</a>]. The WBC count was ≥15,000/microL in the only infant with concomitant meningitis, 6 of 10 infants with a clinical diagnosis of sepsis or shock, and all 3 infants with concomitant urinary tract infection. In a retrospective series of 41 patients with neonatal mastitis, the WBC count was elevated (&gt;15,000 WBC/microL) in 46 percent [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood culture</strong> – Blood culture results help to guide antimicrobial therapy if a pathogen is identified.</p><p></p><p class="bulletIndent1">In a retrospective multicenter cohort of 657 infants with mastitis, blood cultures were obtained in 581 (88 percent) [<a href="#rid8">8</a>]. Two infants (0.3 percent) had bacteremia: one with methicillin-resistant <em>S. aureus</em> (MRSA) and one with group B <em>Streptococcus</em>; both grew MRSA from site cultures. Both infants were &lt;28 days of age and neither was febrile, ill appearing, or had a WBC count ≥15,000/microL. Contaminants were isolated from 25 blood cultures (4.3 percent). In earlier studies, blood cultures were positive in approximately 4 percent of cases but potential contaminants were included [<a href="#rid3">3,18-20,29-31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gram stain and culture</strong> – If possible, we also try to isolate the pathogen directly from the breast infection. We perform Gram stain and culture (aerobic and anaerobic) of nipple drainage (if present) and of abscess fluid (in infants with breast abscess as indicated by fluctuance) [<a href="#rid3">3,6,7</a>]. The abscess fluid sample may be obtained by aspiration (with or without ultrasonographic guidance) or incision and drainage [<a href="#rid3">3,7,30,32</a>]. (See <a class="local">'Drainage of breast abscess'</a> below.)</p><p></p><p class="bulletIndent1">In a multicenter cohort of 657 infants ≤90 days with mastitis (median age 21 days), site cultures were obtained in 335 (51 percent) [<a href="#rid8">8</a>]. Approximately 80 percent of cultures were positive (54 percent for MRSA, 29 percent for methicillin-susceptible <em>S. aureus</em>, and 8 percent for unspecified <em>S. aureus</em>). A smaller case series had similar results [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lumbar puncture if clinically indicated</strong> – We perform cerebrospinal fluid (CSF) cell counts, differential, Gram stain, and culture if clinically indicated [<a href="#rid3">3,14,19</a>]; our indications for lumbar puncture in infants with mastitis who are &lt;2 months of age include (any of the following) [<a href="#rid3">3,8,23</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ill appearance (eg, poor appetite, lethargy, abscess)</p><p class="bulletIndent2"><span class="glyph">•</span>Temperature ≥38°C [100.4°F] or, for infants &lt;28 days, subjective report of fever at home (eg, "tactile temperature" or "felt warm")</p><p class="bulletIndent2"><span class="glyph">•</span>WBC count ≥15,000/microL or ≤5000/microL</p><p></p><p class="bulletIndent1">Positive CSF cultures are rare in infants with mastitis. In a multicenter retrospective study of 657 infants ≤90 days with mastitis (median age 21 days), CSF cultures were obtained in 216 (33 percent) and positive in only one [<a href="#rid8">8</a>]. The six-day-old infant was febrile but not described as ill appearing, grew MRSA from the CSF and site culture, and had a peripheral WBC count of 24,600/microL, a CSF WBC count of 44/microL, and a CSF red blood cell count of 15,600/microL.</p><p></p><p class="bulletIndent1">Neonates and young infants with <em>S. aureus</em> mastitis (particularly methicillin-resistant <em>S. aureus</em> strain USA300) may have substantial CSF pleocytosis with sterile CSF cultures, whether or not they have systemic symptoms [<a href="#rid30">30</a>]. If CSF is obtained after initiation of antimicrobial therapy, the culture may be unreliable, and infants with mastitis-related pleocytosis may receive unnecessary treatment for meningitis.</p><p></p><p class="bulletIndent1">The evaluation of the febrile or ill-appearing infant is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6467.html" rel="external">"Approach to the ill-appearing infant (younger than 90 days of age)"</a> and  <a class="medical medical_review" href="/z/d/html/6072.html" rel="external">"The febrile infant (29 to 90 days of age): Outpatient evaluation", section on 'Focal infection'</a> and  <a class="medical medical_review" href="/z/d/html/134347.html" rel="external">"The febrile neonate (28 days of age or younger): Outpatient evaluation and initial management", section on 'Focal infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urine culture if clinically indicated </strong>– We obtain a catheterized urine specimen for culture in infants &lt;28 days of age with WBC counts ≥15,000/microL and temperature ≥38°C [100.4°F] or subjective fever.</p><p></p><p class="bulletIndent1">In a retrospective multicenter cohort of 657 infants with mastitis, urine culture was obtained in 274 (42 percent) [<a href="#rid8">8</a>]. Three infants, all &lt;28 days of age, had a concomitant urinary tract infection. Two infants were febrile and all three had WBC counts ≥15,000/microL. In one, the site culture and urine both isolated <em>E. coli.</em> In the other two infants without site cultures, the urine pathogens were <em>Klebsiella</em> and <em>E. coli.</em></p><p></p><p class="headingAnchor" id="H16"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H70399819"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>Supportive care for infants with mastitis includes application of warm compresses. Caregivers should be discouraged from palpation of the breast and expression of fluid from the nipple.</p><p class="headingAnchor" id="H2302027660"><span class="h2">Drainage of breast abscess</span><span class="headingEndMark"> — </span>In addition to antimicrobial therapy, breast abscess may require aspiration and/or incision and drainage (for both diagnosis and treatment), unless spontaneous drainage occurs [<a href="#rid2">2,3,32,33</a>].</p><p>During drainage, care must be taken to avoid the breast bud [<a href="#rid5">5,33,34</a>]. If incision and drainage is necessary, it should be performed by appropriately trained personnel (eg, a breast surgeon, breast radiologist, or pediatric surgeon) because of the potential for breast hypoplasia or scarring after this procedure [<a href="#rid3">3,4</a>]. (See  <a class="medical medical_review" href="/z/d/html/102.html" rel="external">"Breast disorders in children and adolescents", section on 'Breast asymmetry'</a>.)</p><p class="headingAnchor" id="H3998125186"><span class="h2">Antimicrobial therapy</span></p><p class="headingAnchor" id="H2695868686"><span class="h3">Route of empiric therapy</span><span class="headingEndMark"> — </span>We initiate treatment for mastitis in infants &lt;2 months parenterally because of the potential for progression to abscess with oral treatment and the prevalence of community-associated methicillin-resistant <em>S. aureus</em> (CA-MRSA) [<a href="#rid2">2,3,7,30</a>]. One small series noted that all five patients who were treated with oral <a class="drug drug_pediatric" data-topicid="12639" href="/z/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> before presentation developed breast abscesses despite susceptibility to amoxicillin-clavulanate [<a href="#rid2">2</a>].</p><p>No randomized controlled studies have evaluated antibiotic regimens for infant mastitis. Our recommendations for treatment are based upon the frequency of causative pathogens and the response to therapy described in observational studies [<a href="#rid2">2,7,18,30,35</a>].</p><p class="headingAnchor" id="H3352425977"><span class="h3">Choice of regimen</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe complications, including extensive cellulitis, necrotizing fasciitis, osteomyelitis, and shock </strong>– For infants &lt;2 months with mastitis or breast abscess and severe complications, including cellulitis (cellulitis extending beyond the skin overlying the breast bud), necrotizing fasciitis, osteomyelitis, and shock, we provide parenteral antimicrobial therapy with broad empiric coverage for methicillin-resistant <em>S. aureus</em> (MRSA), methicillin-susceptible <em>S. aureus</em>, and gram-negative organisms. For example  (<a class="graphic graphic_table graphicRef111097" href="/z/d/graphic/111097.html" rel="external">table 1</a>) [<a href="#rid30">30</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For infants with normal cerebrospinal fluid (CSF) profile:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">Vancomycin</a> plus <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">nafcillin</a> plus <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> (if the infant is not also receiving or expected to receive calcium-containing intravenous [IV] fluids or parenteral nutrition), or</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">Vancomycin</a> plus <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">nafcillin</a> plus <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">gentamicin</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For infants with abnormal CSF profile:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">Vancomycin</a> plus <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">nafcillin</a> plus <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> (if available), or</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">Vancomycin</a> plus <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">nafcillin</a> plus <a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">ceftazidime</a>, or</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">Vancomycin</a> plus <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">nafcillin</a> plus <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> (if the infant is not also receiving or expected to receive calcium-containing IV fluids or parenteral nutrition)</p><p></p><p class="bulletIndent1">IV <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> should be avoided in neonates who are also receiving or expected to receive calcium-containing IV fluids or parenteral nutrition because of the potential for life-threatening adverse drug reactions [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1">Therapy should be altered according to culture results once they are available. Treatment of invasive MRSA infections is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6057.html" rel="external">"<i>Staphylococcus aureus </i>in children: Overview of treatment of invasive infections", section on 'Treatment of neonates'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No severe complications</strong> – For infants &lt;2 months with mastitis or breast abscess without severe complications, the initial parenteral regimen is guided by the Gram stain, if one is available, and local susceptibility patterns  (<a class="graphic graphic_table graphicRef111097" href="/z/d/graphic/111097.html" rel="external">table 1</a>) [<a href="#rid2">2,3,19,28,30</a>]. Therapy should be altered according to culture results once they are available.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gram-positive cocci</strong> – If gram-positive cocci are identified, empiric therapy should include coverage for <em>S. aureus </em> (<a class="graphic graphic_table graphicRef111097" href="/z/d/graphic/111097.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In communities where CA-MRSA infections are rare, a penicillinase-resistant antibiotic (eg, <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">oxacillin</a> or <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">nafcillin</a>) may be used.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In areas with an increased incidence of CA-MRSA (more than 10 percent of community isolates), <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> or <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a> is appropriate [<a href="#rid30">30</a>]. Clindamycin may be used if central nervous system infection is not a concern  (<a class="graphic graphic_table graphicRef111097" href="/z/d/graphic/111097.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/6057.html" rel="external">"<i>Staphylococcus aureus </i>in children: Overview of treatment of invasive infections", section on 'Treatment of neonates'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gram-negative organisms</strong> – If gram-negative organisms are identified, empiric therapy should include an aminoglycoside (eg, <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">gentamicin</a>, <a class="drug drug_pediatric" data-topicid="12541" href="/z/d/drug information/12541.html" rel="external">amikacin</a>) or third-generation cephalosporin (eg, <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a>, <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a>, <a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">ceftazidime</a>). Cefotaxime (preferred if available), ceftriaxone, or ceftazidime is recommended if CSF is abnormal  (<a class="graphic graphic_table graphicRef111097" href="/z/d/graphic/111097.html" rel="external">table 1</a>). Intravenous ceftriaxone should be avoided in infants who are also receiving or are expected to receive intravenous calcium in IV fluids or parenteral nutrition [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gram stain not available or no organisms seen</strong> – If the Gram stain is not available or if no organisms are seen, we provide empiric coverage for <em>S. aureus</em> and gram-negative enteric organisms  (<a class="graphic graphic_table graphicRef111097" href="/z/d/graphic/111097.html" rel="external">table 1</a>) [<a href="#rid4">4,6,30</a>].</p><p></p><p class="headingAnchor" id="H1249461799"><span class="h3">Duration of therapy</span><span class="headingEndMark"> — </span>The duration of therapy depends upon the clinical response; a total of 7 to 14 days (parenteral and oral) is usually adequate [<a href="#rid2">2,3,18,30</a>].</p><p>Infants with uncomplicated mastitis or breast abscess may be transitioned from parenteral to oral therapy if all of the following criteria are met:</p><p class="bulletIndent1"><span class="glyph">●</span>Resolution of systemic symptoms and fever</p><p class="bulletIndent1"><span class="glyph">●</span>Improvement in other clinical findings</p><p class="bulletIndent1"><span class="glyph">●</span>Antibiotic susceptibility results are available</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic bacterial cultures (blood, CSF) isolate no pathogens after 48 hours of incubation</p><p></p><p>Infants receiving oral antibiotics should be followed closely (eg, by phone, virtual, and/or office visits) to assess medication adherence and response to therapy; treatment failure may be an indication for abscess drainage (or repeat drainage). One retrospective study of neonates with skin and soft tissue infections discharged with oral antibiotics found only 3 of 46 infants (6 percent) had treatment failure. All pathogens were clindamycin-resistant <em>S. aureus</em> [<a href="#rid16">16,30,37</a>]. (See <a class="local">'Response to therapy'</a> below.)</p><p class="headingAnchor" id="H2391597990"><span class="h1">RESPONSE TO THERAPY</span></p><p class="headingAnchor" id="H839504582"><span class="h2">Monitoring response</span><span class="headingEndMark"> — </span>Response to therapy is indicated by clinical improvement within 24 to 48 hours of appropriate antibiotic therapy.</p><p class="headingAnchor" id="H3545075744"><span class="h2">Failure to respond</span><span class="headingEndMark"> — </span>For infants who worsen or fail to improve after 48 hours of initial therapy, possible explanations include:</p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate drainage (if drainage was performed), abscess recurrence, or development of a new abscess</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate empiric therapy (for those with negative cultures or in whom cultures were not obtained)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alternative diagnosis (eg, physiologic breast hypertrophy, hemangioma, lymphangioma) (see <a class="local">'Differential diagnosis'</a> above)</p><p></p><p>Ultrasonography may identify residual, recurrent, or new abscesses that require drainage, particularly if induration makes it difficult to assess fluctuance, and can be used to guide the drainage procedure [<a href="#rid38">38</a>]. Ultrasonography also may be helpful in identifying alternative diagnoses. (See <a class="local">'Drainage of breast abscess'</a> above.)</p><p>If cultures remain negative (or were not obtained) and ultrasonography does not identify lesions that require drainage or alternative diagnoses, a change in empiric therapy may be indicated (eg, to include activity against methicillin-resistant <em>S. aureus</em> [MRSA] if it was not included initially or for less common pathogens if MRSA coverage was initially included) [<a href="#rid6">6,30,32,33</a>]. In such cases, consultation with an expert in infectious diseases is suggested.</p><p class="headingAnchor" id="H2868163914"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>There are few data regarding the long-term outcome of mastitis [<a href="#rid2">2</a>]. Most patients have an excellent prognosis, but there are case reports of breast asymmetry following incision and drainage for breast abscess during infancy [<a href="#rid1">1,4,39</a>]. Recurrences are rare, but patients should be followed closely [<a href="#rid3">3</a>]. Patients with <em>S. aureus</em> mastitis are at risk for subsequent <em>S. aureus</em> infections at other sites [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/6065.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus </i>infections in children: Epidemiology and clinical spectrum"</a>.)</p><p class="headingAnchor" id="H2551026329"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110086.html" rel="external">"Society guideline links: Skin and soft tissue infections"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Most cases of mastitis and breast abscess in infants are caused by <em>Staphylococcus aureus</em>. Less common causes include gram-negative enteric organisms, anaerobes, and group B <em>Streptococcus.</em> (See <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During the first year of life, mastitis typically occurs in infants younger than two months of age. A clinical diagnosis of mastitis can be made in infants with characteristic clinical findings: unilateral swelling, erythema, warmth, tenderness, and/or induration of the breast  (<a class="graphic graphic_picture graphicRef110965" href="/z/d/graphic/110965.html" rel="external">picture 1</a>). Fluctuance indicates breast abscess. Ultrasonography is not necessary but can confirm the diagnosis of mastitis or breast abscess if the diagnosis is uncertain. Systemic findings (eg, fever, poor feeding) are an indication of more severe disease. (See <a class="local">'Clinical features'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We obtain a complete blood count with differential and blood culture before the initiation of antimicrobial therapy. We also obtain Gram stain and culture of nipple drainage (if present) and abscess fluid (if abscess is present). We obtain cerebrospinal fluid (CSF) in infants &lt;2 months who are ill-appearing (eg, poor appetite, lethargy, abscess), febrile (≥38°C [100.4°F]) or subjective fever if &lt;28 days of age, or have white blood cell count ≥15,000/microL or &lt;5000/microL. (See <a class="local">'Additional evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Breast abscess may require aspiration and/or incision and drainage in addition to antimicrobial therapy unless spontaneous drainage occurs. Incision and drainage should be performed by appropriately trained personnel (eg, a breast surgeon, breast radiologist, or pediatric surgeon). (See <a class="local">'Drainage of breast abscess'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In infants &lt;2 months of age with mastitis or breast abscess, we provide initial antimicrobial therapy parenterally. (See <a class="local">'Antimicrobial therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For infants with mastitis or breast abscess and severe complications (eg, cellulitis extending beyond the skin overlying the breast bud, necrotizing fasciitis, osteomyelitis, and shock), we provide parenteral antimicrobial therapy with broad empiric coverage for methicillin-resistant <em>S. aureus</em>, methicillin-susceptible <em>S. aureus</em>, and gram-negative organisms (eg, <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> plus <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">nafcillin</a> plus one of the following: <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">gentamicin</a>, <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a>, <a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">ceftazidime</a>, or <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a>). Intravenous ceftriaxone should be avoided in infants who are also receiving or are expected to receive intravenous calcium in intravenous fluids or parenteral nutrition because of the potential for life-threatening adverse drug reactions. (See <a class="local">'Choice of regimen'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The empiric antibiotic regimen for infants without severe complications is determined by the Gram stain (if available) and local susceptibility patterns  (<a class="graphic graphic_table graphicRef111097" href="/z/d/graphic/111097.html" rel="external">table 1</a>). Therapy should be altered according to culture results once they are available. (See <a class="local">'Choice of regimen'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most patients have an excellent prognosis. However, there are case reports of breast asymmetry following incision and drainage for breast abscess during infancy. Recurrences are rare. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Faden H. Mastitis in children from birth to 17 years. Pediatr Infect Dis J 2005; 24:1113.</a></li><li><a class="nounderline abstract_t">Stricker T, Navratil F, Sennhauser FH. Mastitis in early infancy. Acta Paediatr 2005; 94:166.</a></li><li><a class="nounderline abstract_t">Walsh M, McIntosh K. Neonatal mastitis. Clin Pediatr (Phila) 1986; 25:395.</a></li><li><a class="nounderline abstract_t">Rudoy RC, Nelson JD. Breast abscess during the neonatal period. A review. Am J Dis Child 1975; 129:1031.</a></li><li><a class="nounderline abstract_t">Efrat M, Mogilner JG, Iujtman M, et al. Neonatal mastitis--diagnosis and treatment. Isr J Med Sci 1995; 31:558.</a></li><li><a class="nounderline abstract_t">Brook I. The aerobic and anaerobic microbiology of neonatal breast abscess. Pediatr Infect Dis J 1991; 10:785.</a></li><li><a class="nounderline abstract_t">Montague EC, Hilinski J, Andresen D, Cooley A. Evaluation and treatment of mastitis in infants. Pediatr Infect Dis J 2013; 32:1295.</a></li><li><a class="nounderline abstract_t">Kaplan RL, Cruz AT, Michelson KA, et al. Neonatal Mastitis and Concurrent Serious Bacterial Infection. Pediatrics 2021; 148.</a></li><li><a class="nounderline abstract_t">Stetler H, Martin E, Plotkin S, Katz M. Neonatal mastitis due to Escherichia coli. J Pediatr 1970; 76:611.</a></li><li><a class="nounderline abstract_t">Burry VF, Beezley M. Infant mastitis due to gram-negative organisms. Am J Dis Child 1972; 124:736.</a></li><li><a class="nounderline abstract_t">Schwarz MD, Rosen RA. Neonatal mastitis due to E. coli. Clin Pediatr (Phila) 1974; 13:86.</a></li><li><a class="nounderline abstract_t">McGuigan MA, Lipman RP. Neotal mastitis due to Proteus mirabilis. Am J Dis Child 1976; 130:1296.</a></li><li><a class="nounderline abstract_t">Rench MA, Baker CJ. Group B streptococcal breast abscess in a mother and mastitis in her infant. Obstet Gynecol 1989; 73:875.</a></li><li><a class="nounderline abstract_t">Sloan B, Evans R. Clinical pearls: neonatal breast mass. Acad Emerg Med 2003; 10:269.</a></li><li><a class="nounderline abstract_t">Fortunov RM, Hulten KG, Hammerman WA, et al. Community-acquired Staphylococcus aureus infections in term and near-term previously healthy neonates. Pediatrics 2006; 118:874.</a></li><li><a class="nounderline abstract_t">Montalto M, Lui B. MRSA as a cause of postpartum breast abscess in infant and mother. J Hum Lact 2009; 25:448.</a></li><li><a class="nounderline abstract_t">Jean Bertrand KA, Rose NK, Franck LG, et al. Mastitis and breast abscess in newborns and infants. Afr J Paediatr Surg 2022; 19:238.</a></li><li><a class="nounderline abstract_t">Al Ruwaili N, Scolnik D. Neonatal mastitis: controversies in management. J Clin Neonatol 2012; 1:207.</a></li><li><a class="nounderline abstract_t">Stauffer WM, Kamat D. Neonatal mastitis. Pediatr Emerg Care 2003; 19:165.</a></li><li class="breakAll">Fortunov R, Mednax/Pediatrix Medical Group, 2009, personal communication.</li><li><a class="nounderline abstract_t">Michael IK, Howard FH. Osteomyelitis due to penicillin-resistant staphylococci in infancy following suppurative mastitis. (Report of a case). J Trop Pediatr 1960; 6:19.</a></li><li><a class="nounderline abstract_t">Hsieh WS, Yang PH, Chao HC, Lai JY. Neonatal necrotizing fasciitis: a report of three cases and review of the literature. Pediatrics 1999; 103:e53.</a></li><li><a class="nounderline abstract_t">Nelson JD. Suppurative mastitis in infants. Am J Dis Child 1973; 125:458.</a></li><li><a class="nounderline abstract_t">Bodemer C, Panhans A, Chretien-Marquet B, et al. Staphylococcal necrotizing fasciitis in the mammary region in childhood: a report of five cases. J Pediatr 1997; 131:466.</a></li><li><a class="nounderline abstract_t">Díaz ÁM, Céspedes BO, Rodríguez MS. Parotid abscess and mastitis by methicillin-resistant Staphylococcus aureus in a newborn. Rev Cubana Pediatr 2018; 90:e621.</a></li><li><a class="nounderline abstract_t">D'Auria D, Ferrara D, Aragione N, et al. Role of ultrasound in diagnosis of neonatal breast enlargement: a newborn case report. Radiol Case Rep 2021; 16:2692.</a></li><li><a class="nounderline abstract_t">Pant VP, Mishra D. Neonatal giant mastauxe: a case report. Ann Med Surg (Lond) 2023; 85:4134.</a></li><li class="breakAll">Fleisher, GR. Infectious disease emergencies. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM (Eds), Liippincott Williams &amp; Wilkins, Philadelphia 2006. p.783.</li><li><a class="nounderline abstract_t">Day CT, Kaplan SL, Mason EO, Hulten KG. Community-associated Staphylococcus aureus infections in otherwise healthy infants less than 60 days old. Pediatr Infect Dis J 2014; 33:98.</a></li><li><a class="nounderline abstract_t">Fortunov RM, Hulten KG, Hammerman WA, et al. Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates. Pediatrics 2007; 120:937.</a></li><li class="breakAll">Torres-Day C, Baylor College of Medicine, 2013, personal communication.</li><li class="breakAll">DiVasta AD, Weldon CB, Labow BI. The breast: Examination and lesions. In: Emans, Laufer, Goldstein's Pediatric &amp; Adolescent Gynecology, 7th ed, Emans SJ, Laufer MR, DiVasta AD (Eds), Wolters Kluwer, Philadelphia 2020. p.781.</li><li><a class="nounderline abstract_t">Schwarz RJ, Shrestha R. Needle aspiration of breast abscesses. Am J Surg 2001; 182:117.</a></li><li class="breakAll">Baren JM. Breast lesions. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p.193.</li><li><a class="nounderline abstract_t">Masoodi T, Mufti GN, Bhat JI, et al. Neonatal mastitis: a clinico-microbiological study. J Neonatal Surg 2014; 3:2.</a></li><li><a class="nounderline abstract_t">Bradley JS, Wassel RT, Lee L, Nambiar S. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics 2009; 123:e609.</a></li><li><a class="nounderline abstract_t">Patel P, Foster CE, Stimes G, et al. Risk Factors for Treatment Failure in Neonates With Skin and Soft Tissue Infection: A Retrospective Cohort Study. Clin Pediatr (Phila) 2023; :99228231189132.</a></li><li><a class="nounderline abstract_t">Borders H, Mychaliska G, Gebarski KS. Sonographic features of neonatal mastitis and breast abscess. Pediatr Radiol 2009; 39:955.</a></li><li><a class="nounderline abstract_t">Panteli C, Arvaniti M, Zavitsanakis A. Long-term consequences of neonatal mastitis. Arch Dis Child 2012; 97:673.</a></li></ol></div><div id="topicVersionRevision">Topic 5974 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16371879" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mastitis in children from birth to 17 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15981749" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mastitis in early infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3731667" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Neonatal mastitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1103616" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Breast abscess during the neonatal period. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7558780" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Neonatal mastitis--diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1945584" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The aerobic and anaerobic microbiology of neonatal breast abscess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24145956" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evaluation and treatment of mastitis in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34187909" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Neonatal Mastitis and Concurrent Serious Bacterial Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4911906" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Neonatal mastitis due to Escherichia coli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4563751" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Infant mastitis due to gram-negative organisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4588669" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Neonatal mastitis due to E. coli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/790942" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Neotal mastitis due to Proteus mirabilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2649829" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Group B streptococcal breast abscess in a mother and mastitis in her infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12615593" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical pearls: neonatal breast mass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16950976" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Community-acquired Staphylococcus aureus infections in term and near-term previously healthy neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19589942" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : MRSA as a cause of postpartum breast abscess in infant and mother.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36018205" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mastitis and breast abscess in newborns and infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24027728" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Neonatal mastitis: controversies in management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12813301" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Neonatal mastitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12813301" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Neonatal mastitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Osteomyelitis due to penicillin-resistant staphylococci in infancy following suppurative mastitis. (Report of a case).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10103345" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Neonatal necrotizing fasciitis: a report of three cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4571961" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Suppurative mastitis in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9329431" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Staphylococcal necrotizing fasciitis in the mammary region in childhood: a report of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Parotid abscess and mastitis by methicillin-resistant Staphylococcus aureus in a newborn</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34336074" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Role of ultrasound in diagnosis of neonatal breast enlargement: a newborn case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37554865" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Neonatal giant mastauxe: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37554865" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Neonatal giant mastauxe: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23934207" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Community-associated Staphylococcus aureus infections in otherwise healthy infants less than 60 days old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17974729" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17974729" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17974729" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11574080" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Needle aspiration of breast abscesses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11574080" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Needle aspiration of breast abscesses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26023473" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Neonatal mastitis: a clinico-microbiological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19289450" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37491834" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Risk Factors for Treatment Failure in Neonates With Skin and Soft Tissue Infection: A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19506847" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Sonographic features of neonatal mastitis and breast abscess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22550321" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Long-term consequences of neonatal mastitis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
